Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients
Authors:
- 15 October 2005
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (20) , 7470-7479
Abstract
Purpose: The E75 peptide is an immunogenic peptide from the HER-2/neu protein that is substantially expressed in prostate cancer. We are conducting a clinical trial of an E75/granulocyte macrophage colony-stimulating factor vaccine to prevent post-prostatectomy prostate-specific antigen (PSA) recurrences in high-risk prostate cancer (HRPC) patients.Keywords
This publication has 30 references indexed in Scilit:
- The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trialThe Prostate, 2004
- Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based VaccinesJournal of Clinical Oncology, 2002
- Vaccination against the HER-2/neu oncogenic protein.Endocrine-Related Cancer, 2002
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- PREDICTING RISK OF PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY WITH THE CENTER FOR PROSTATE DISEASE RESEARCH AND CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR DATABASESJournal of Urology, 2001
- Frequencies of HLA-A2 alleles in five U.S. population groupsHuman Immunology, 2000
- Treatment of prostate cancerJournal of Clinical Pharmacy and Therapeutics, 1999
- Association of gastric adenocarcinoma with the HLA class II gene DQB10301Gastroenterology, 1996
- Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.Journal of Experimental Medicine, 1995
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989